BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » clinical trial

Pluristem Therapeutics, Interview with Yaky Yanay, President and Co-CEO

March 28, 2019 By Cade Hildreth (CEO) 1 Comment

Placental cell therapies

Pluristem TherapeuticsPluristem Therapeutics (PSTI) is a clinical-stage company that is a proprietary 3D manufacturing technology to develop placental cell therapies for conditions that include ischemia, muscle injury, and exposure to radiation. I had the honor of interviewing Mr. Yaky Yanay, President and Co-CEO of Pluristem Therapeutics.

In this interview, we discuss the history of Pluristem Therapeutics, its clinical-stage products, intellectual property (IP) portfolio, marketing strategy and future directions.

Enjoy these insights into Pluristem Therapeutics, a world-class leader in cell therapy manufacturing and placental-derived products. [Read more…]

Filed Under: Interviews, MSCs Tagged With: clinical trial, interview, placental, Pluristem

Cynata’s iPSC-derived Cell Therapeutic
(CYP-001) Meets Safety & Efficacy Endpoints

September 3, 2018 By Cade Hildreth (CEO) 2 Comments

Cynata Phase II Trial Data

Cynata TherapeuticsCynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Cynata is the only company in the world that can mass-produce therapeutic mesenchymal stem cells deriving from a single donor at a consistent quality and affordable cost. [Read more…]

Filed Under: iPS Cells, Stem Cell News Tagged With: clinical trial, cynata therapeutics

Preliminary Results From BioCardia’s Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal

August 24, 2018 By Cade Hildreth (CEO) Leave a Comment

BioCardia Helix

BioCardia - CardiAMP Heart Failure Trial SAN CARLOS, Calif., Aug. 22, 2018 — In a Viewpoint paper published online today in Circulation Research, the Phase III CardiAMP Heart Failure Trial (CardiAMP-HF Trial) studying the investigational CardiAMP stem cell therapy from BioCardia®, Inc. (OTC: BCDA) was highlighted as an example of personalized medicine, with promising results from the first 10 patients in the roll-in cohort reported. The company believes this to be the first outcomes data published from any pivotal trial of a stem cell therapy for heart failure. The paper is authored by Peter Johnston, M.D., Eric Duckers, M.D., Ph.D., Amish Raval, M.D., Thomas Cook, Ph.D. and Carl Pepine, M.D. [Read more…]

Filed Under: Press Releases, Stem Cells Tagged With: BioCardia, cardiac, clinical trial

Steminent Announces Japan partner ReproCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan

August 7, 2018 By Cade Hildreth (CEO) 1 Comment

ReproCELL and Steminent PartnerSan Diego, CA, USA, August 1st, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the Clinical Trial Notification (“CTN”), submitted by their Japan partner; ReproCELL, to the Japan Pharmaceuticals and Medical Device Agency (“PMDA”) for a Stemchymal® SCA Phase II clinical trial for Polyglutamine Spinocerebellar Ataxia (“PolyQ SCA”) has been approved. This is another key milestone for Steminent’s international Stemchymal® SCA Phase II clinical development program with trials now moving ahead in Taiwan, US, and Japan.  [Read more…]

Filed Under: Press Releases, Stem Cells Tagged With: clinical trial, ReproCELL, Steminent

Parkinson’s Disease Clinical Trial to Launch in Japan | iPS Cell Trial

August 6, 2018 By Cade Hildreth (CEO) Leave a Comment

iPS cell clinical trial parkinson's disease

Japan will continue its dominance with iPS cell clinical trials with the launch of a physician-lead trial for Parkinson’s disease. In its July 2018 press announcement, Kyoto University announced that its University Hospital and the Center for iPS Cell Research and Application (CiRA) will launch the world’s first clinical trial for Parkinson’s disease to utilize an induced pluripotent stem cell (iPS cell) derived therapeutic product.

Existing iPS Cell Trials

This newest iPS cell trial represents only the third iPS cell trial to be undertaken worldwide. The other existing iPS cell trials are being conducted by the RIKEN Center for Developmental Biology (CDC) and Cynata Therapeutics (ASX:CYP), respectively. [Read more…]

Filed Under: iPS Cells Tagged With: clinical trial, cynata therapeutics, parkinson's disease, RIKEN

  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Cell Therapy Manufacturing Survey - Selection Criteria for Choosing a CMO Partner
    评分 0 / 5
    $197 $97
  • Stem Cell Fact Sheet - Types of Stem Cells and their Use in Medicine
    评分 0 / 5
    $10
  • Global Database of Research Supply Companies Global Database of Research Supply Companies 2021
    评分 0 / 5
    $39
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.